Oral presentations related to multiple myeloma will take place on three days during the 2016 American Society of Clinical Oncology (ASCO) annual meeting.

The majority of the myeloma-related oral presentations will take place during an afternoon session on Friday, June 3. There is one myeloma-related late breaking abstract, which will be presented the late-breaking abstract session in the afternoon on Sunday, June 5. All the remaining myeloma-related oral presentations will be during a session in the morning on Tuesday, June 7.

The list below contains the titles and authors of all multiple myeloma oral presentations at ASCO 2016. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.

Links to PDF files containing presentation slides will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.

Please note that this list does not include summary / review presentations that take place during some sessions, nor does it include education session presentations.

This edition of Myeloma Morning gives a quick overview of the myeloma-related oral presentations at the ASCO 2016 meeting.

The Beacon also has complete lists of all ASCO 2016 multiple myeloma-related poster presentations, education session presentations, and e-abstracts, as well as news articles about multiple myeloma at the ASCO 2016 meeting.

We want to thank the Beacon's sponsors for making it possible for The Beacon to provide this and other important news, information, and support to the multiple myeloma community worldwide.

8000 - Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial)

Michele Cavo, Antonio Palumbo, Sonja Zweegman, Meletios A. Dimopoulos, Roman Hajek, Lucia Pantani, Meral Beksac, Ruth Wester, Hans E. Johnsen, Ulf-Henrik Mellqvist, Maria Teresa Petrucci, Christoph Driessen, Francesco Di Raimondo, Rossella Troia, Annalisa Pezzi, Bronno van der Holt, Ka Lung Wu, Heinz Ludwig, Francesca Gay, Pieter Sonneveld (abstract)

8001 - Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS)

Michel Attal, Antonio Palumbo, Sarah A. Holstein, Valerie Lauwers-Cances, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Kenneth Carl Anderson, Denis Caillot, Valeria Magarotto, Philippe Moreau, Gerald Marit, Zhinuan Yu, Philip L. McCarthy (abstract, presentation slides [PDF] courtesy of Dr. McCarthy)

8002 - Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM)

Martha Lacy, P. Leif Bergsagel, Betsy LaPlant, Alese Halvorson, Francis Buadi, Nelson Leung, Ronald S. Go, David Dingli, Prashant Kapoor, Morie A. Gertz, Yi Lin, Angela Dispenzieri, Yi Lisa Hwa, Amie Fonder, Rafael Fonseca, Suzanne R. Hayman, A. Keith Stewart, Joseph Mikhael, S. Vincent Rajkumar, Shaji Kumar (abstract, presentation slides [PDF] courtesy of Dr. Lacy)

Discussion - Abstracts 8000, 8001, and 8002

William Bensinger (presentation slides [PDF] courtesy of Dr. Bensinger)

8003 - Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients

Sham Mailankody, Neha Korde, Mark J. Roschewski, Austin Christofferson, Martin Boateng, Yong Zhang, Elisabet Esteve Manasanch, Dickran Gano Kazandjian, Mary Kwok, Manisha Bhutani, Nishant Tageja, Adriana Zingone, Rene Costello, Laurence Lamy, Malin Hultcrantz, Elli Papaemmanuil, Maryalice Stetler-Stevenson, William Douglas Figg, Jonathan J Keats, Ola Landgren (abstract, presentation slides [PDF] courtesy of Dr. Mailankody)

8004 - Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM)

Praful Kumar Ravi, Shaji Kumar, Jeremy Todd Larsen, Wilson I. Gonsalves, Francis Buadi, Martha Lacy, Ronald S. Go, Angela Dispenzieri, Prashant Kapoor, John Anthony Lust, Morie A. Gertz, Robert A. Kyle, S. Vincent Rajkumar (abstract)

Discussion - Abstracts 8003 and 8004

Ajai Chari (pre­sentation slides [PDF] courtesy of Dr. Chari)

8005 - Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM)

Joshua Ryan Richter, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, Joseph Mikhael, William Bensinger, Meletios A. Dimopoulos, Todd M. Zimmerman, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Eric Charpentier, Stephen Anthony Strickland, Jesus San Miguel (abstract, presentation slides [PDF] courtesy of Dr. Richter)

8006 - Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Enrique M. Ocio, María-Victoria Mateos, Felipe Prosper, Jesus Martin, Albert Oriol Rocafiguera, Isidro Jarque, Rebeca Iglesias, Cristina Motlloo, Maria Sole, Paula Rodriguez-Otero, Sara Martinez, Eva Fernandez-Garcia, Jean-Marie Michot, Arturo Soto-Matos, Jose Rodriguez Diaz -Pavon, Vincent Ribrag, Jesus San Miguel (abstract, presentation slides [PDF] courtesy of Dr. Mateos)

8007 - Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study

Cara Ann Rosenbaum, Leonor Ano Stephens, Vishal Kukreti, Jeffrey A. Zonder, Craig Cole, Todd M. Zimmerman, Donna Ellen Reece, Jesus G. Berdeja, Erica Severson, Andrea Revethis, Brittany Wolfe, Kathryn McDonnell, Jennifer Nam, Kent A. Griffith, Andrzej J. Jakubowiak (abstract)

8008 - A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results

Amrita Y. Krishnan, Prashant Kapoor, Joycelynne Palmer, Shaji Kumar, Sagar Lonial, Myo Htut, Chatchada Karanes, Nitya Nathwani, Michael Alan Rosenzweig, Firoozeh Sahebi, George Somlo, Lupe Duarte, Stephen J. Forman, Jesus G. Berdeja (abstract, presentation slides [PDF] courtesy of Dr. Krishnan)

Discussion - Abstracts 8005 - 8008

Suzanne Trudel

LBA4 - Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study

Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, Ajay K. Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania T.M. Hungria, María-Victoria Mateos, Tomer Martin Mark, Ming Qi, Jordan Mark Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld (abstract)

Discussion - Abstract LBA4

Paul G. Richardson

8009 - A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts

Ravi Vij, Nikoletta Lendvai, Thomas G. Martin, Rachid C. Baz, Frank Campana, Florent Mazuir, Eric Charpentier, Don M. Benson (abstract, presentation slides [PDF] courtesy of Dr. Vij)

Discussion - Abstract 8009

Rafael Fonseca (pre­sentation slides [PDF] courtesy of Dr. Fonseca)

8010 - Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

María-Victoria Mateos, Robert Z. Orlowski, David Samuel DiCapua Siegel, Donna Ellen Reece, Philippe Moreau, Enrique M. Ocio, Jatin J. Shah, Paula Rodríguez-Otero, Nikhil C. Munshi, David Avigan, Joy Yang Ge, Patricia Maria Marinello, Jesus San Miguel (abstract, presentation slides [PDF] courtesy of Dr. Mateos)

Discussion - Abstract 8010

Hearn Jay Cho (pre­sentation slides [PDF] courtesy of Dr. Cho)

8011 - Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Philippe Moreau, Asher Alban Akmal Chanan-Khan, Andrew Warwick Roberts, Amit Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Susan Diehl, Jaclyn Cordero, Jeremy A Ross, Wijith Munasinghe, Ming Zhu, Ahmed H. Salem, Joel Leverson, Paulo Cesar Maciag, Maria E. Verdugo, Simon J Harrison (abstract)

Discussion - Abstract 8011

Jonathan Kaufman (pre­sentation slides [PDF] courtesy of Dr. Kaufman)